# A Clinical Study to Evaluate the Safety, and Tolerability of BBM-P002 in the Treatment of Parkinson's Disease

> **NCT07195825** · PHASE1 · RECRUITING · sponsor: **Shanghai Xinzhi BioMed Co., Ltd.** · enrollment: 18 (estimated)

## Conditions studied

- PD

## Interventions

- **GENETIC:** Injecting BBM-P002 into the bilateral putamen

## Key facts

- **NCT ID:** NCT07195825
- **Lead sponsor:** Shanghai Xinzhi BioMed Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-12-27
- **Primary completion:** 2027-12-30
- **Final completion:** 2031-12-30
- **Target enrollment:** 18 (ESTIMATED)
- **Last updated:** 2026-01-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07195825

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07195825, "A Clinical Study to Evaluate the Safety, and Tolerability of BBM-P002 in the Treatment of Parkinson's Disease". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07195825. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*